New Key Statistics Module, Z-Score and F-Score
NAS:VYNE Key Ratios
| Market Cap $ M | 37.48 |
| Enterprise Value $ M | -48.29 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.44 |
| Price/Sales | 31.08 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -5.69 |
| Beneish M-Score | -3.6 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 60.20 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | 1.57 |
| EV-to-EBITDA | 1.57 |
| PEG | -- |
| Shares Outstanding M | 14.53 |
| Net Margin (%) | -6,874.47 |
| Operating Margin % | -7,272.81 |
| Pre-tax Margin (%) | -6,738.06 |
| Quick Ratio | 13.02 |
| Current Ratio | 13.02 |
| ROA % (ttm) | -54.08 |
| ROE % (ttm) | -63.96 |
| ROIC % (ttm) | -1,049.39 |
| Dividend Yield % | -- |
| Altman Z-Score | -7.88 |
VYNE Number of Guru Trades
VYNE Volume of Guru Trades
Gurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:VYNE is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
VYNE Therapeutics Inc Insider Transactions
No Available Data
News about NAS:VYNE
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers